Dr. Sebastian Kreuz, a seasoned investor and life-science professional with more than 20 years of experience at Boehringer Ingelheim, has been serving as an Investment Manager at the Boehringer Ingelheim Venture Fund (BIVF) since June 2019 and leads the BIVF EU team as Head since 2025.

Sebastian embarked on his industrial career in 2004, by joining Boehringer Ingelheim as a research scientist. His initial focus was on early drug concept research by applying functional genomics approaches. Over the years, he has held numerous positions of increasing responsibility within Boehringer’s research organization, thereby further expanding his drug discovery expertise across a broad range of disease areas and therapeutic modalities.

Sebastian holds a PhD in Molecular Biology and Immunology, which he obtained from the University of Stuttgart.